Interestingly, we found differential activation of the regulatory modules associated with the neurofibromin-1 (NF1), NFAT, and ETS2 transcription factors to be associated with clinical outcome, which is significant in view of the results of several recent studies linking these transcription factors with the metastatic and cell-growth properties of breast cancer cells [42–46]. Here, ETS2 is linked to breast carcinoma.